Bayesian AI to delineate molecular signatures of patient susceptibility to potential hematologic events in a phase I study of BPM31510 (ubidecarenone) in solid tumors.

Rangaprasad Sarangarajan,Vivek Subbiah,David S. Hong,Michael A. Kiebish,Vivek K. Vishnudas,Eric Grund,Gregory M. Miller,Leonardo Rodrigues,Hedy Dion,Janice Stevens,Viacheslav R Akmaev,Niven R. Narain

Bayesian AI to delineate molecular signatures of patient susceptibility to potential hematologic events in a phase I study of BPM31510 (ubidecarenone) in solid tumors.

2017

Rangaprasad Sarangarajan
Vivek Subbiah
David S. Hong
Michael A. Kiebish
Vivek K. Vishnudas
Eric Grund
Gregory M. Miller
Leonardo Rodrigues
Hedy Dion
Janice Stevens
Viacheslav R Akmaev
Niven R. Narain

e14042Background: BPM 31510 is a ubidecarenone containing nanodispersion elicits anticancer effect by switching cancer cells energy generation from glycolysis to mitochondrial OXPHOS; i.e. reverses...

Keywords:

Pathology
Medicine
Bayesian probability
Cancer cell
Oxidative phosphorylation
Glycolysis
phase i study
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations